WHO ICTRP trial
The prognostic value of serial monitoring of plasma soluble suppression of…
ChiCTR2000041226 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000041226 |
|---|---|
| Public title | The prognostic value of serial monitoring of plasma soluble suppression of tumorigenicity 2 (sST2) in patients hospitalized with acute heart failure: a national multicenter clinical study |
| Scientific title | The prognostic value of serial monitoring of plasma soluble suppression of tumorigenicity 2 (sST2) in patients hospitalized with acute heart failure: a national multicenter clinical study |
| Primary sponsor | Fuwai Hospital, Chinese Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Diagnostic test |
| Phase | 0 |
| Countries | China |
| Conditions | Acute Heart Failure |
| Interventions | Gold Standard:N terminal pro B type natriuretic peptide (NT-proBNP).;Index test:Plasma soluble suppression of tumorigenicity 2 (sST2). |
| Registration date | Dec 22, 2020 |
| Target size | Target condition:5000;Difficult condition:0 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: